UNSPSC 51143404: Belladonna/caffeine/ergotamine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.

UNSPSC 51143404 Belladonna/caffeine/ergotamine/phenobarbital is a Commodity code, but state and local procurement activity under this code does not reflect the abstract pharmaceutical formulation in its name. Instead, recent solicitations show state and local governments using this code to procure naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs to support community health, emergency response, and pharmacy benefit objectives. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances, reflecting demand across public health infrastructure and employee benefit administration rather than a single agency type.

Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with a March 26, 2026, response deadline and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Activity centers on Florida, Minnesota, Texas, and affiliated jurisdictions within cooperative purchasing networks, with recent opportunities spanning emergency response procurement, statewide generic-pharmaceutical distribution, and emerging direct-contracting pharmacy models.